Bahrain
Kuwait
Oman
Middle East
GDN Online App available on
App Store / Play Store
Gulf Daily News Gulf Daily News
Gulf Daily News Gulf Daily News Gulf Daily News Gulf Daily News Gulf Daily News
Thursday, November 21, 2019 ARCHIVES  |  SEARCH  |  POST ADS  |  ADVERTISE  |  SUBSCRIBE   |  LOGIN   |  CONTACT US

AstraZeneca boosted by good results for biotech asthma drug

International Business
Tue, 17 May 2016
Reuters


AstraZeneca's drive to rebuild its portfolio of new medicines received a boost on Tuesday with positive results for a biotech drug for severe asthma that the company has previously flagged as a potential $2 billion-a-year product.

The antibody treatment benralizumab, which will compete against rivals including GlaxoSmithKline's  recently launched Nucala, was well tolerated and succeeded in reducing asthma attacks in two pivotal late-stage clinical trials.

AstraZeneca said it planned to submit the product for regulatory approval in the United States and Europe in the second half of 2016.

You Might Like